You are here

Article Text

Article menu
Download PDFPDF
Some problems found in HIV-1 RNA quantification
  1. Satoru Yoshida1,
  2. Nozomi Yusa1,
  3. Noriharu Sato1,
  4. Mieko Goto2,
  5. Aikichi Iwamoto2
  1. 1Department of Laboratory Medicine, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108–8639, Japan
  2. 2Department of Infectious Diseases and Applied Immunology, Institute of Medical Science, University of Tokyo

    https://doi.org/10.1136/jcp.53.8.645-a

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      The polymerase chain reaction (PCR) based assay of human immunodeficiency virus type 1 (HIV-1) RNA in plasma is now commercially available and is used widely for the assessment of antiretroviral treatments. The kit is called the AmplicorTM HIV-1 monitor test kit version 1.0 from Roche Diagnostics (Tokyo, Japan). However, this system is not sensitive enough for the accurate measurement of genetic subtypes A and E, and it gives falsely low titres for these virus subtypes.1,2 To surmount this problem, additional gag primers (AG primers) have been provided by Roche for research use (Ver. 1.0 plus). Furthermore, a new improved version (Ver. 1.5) was developed recently, which is said to yield accurate results not only on subtype B but on subtypes A and E. With the Ver. 1.0 plus kit, adding the AG primer set from the Ver. 1.5 kit to the PCR master mixture containing the Ver. 1.0 primer set makes it possible to amplify even subtype A and E viruses. In the Ver. 1.5 kit, …

      View Full Text